Literature DB >> 10909851

Molecular characterisation of 10 Dutch properdin type I deficient families: mutation analysis and X-inactivation studies.

R van den Bogaard1, C A Fijen, M G Schipper, L de Galan, E J Kuijper, M M Mannens.   

Abstract

Properdin type I deficiency is characterised by complete absence of extracellular properdin, a positive regulator of the alternative pathway of complement activation. Properdin deficiency is associated with increased susceptibility to severe meningococcal disease. We have identified the genetic defect in 10 Dutch families. Six different mutations and one sequence polymorphism in the properdin gene were found. All amino acid substitutions were limited to conserved amino acids in exons 7 and 8 in contrast to the premature stops that were found in other exons. The missense mutations may alter the protein conformation in such a way that properdin will not be secreted and therefore catabolised intracellularly. The decreased properdin levels found in some healthy females carrying one mutated properdin gene were studied for X-inactivation. Most carriers with extreme low or high properdin levels showed preferential X-inactivation for the normal or mutated X chromosome, respectively. We observed some exceptions, suggesting additional regulation of properdin excretion apart from X-inactivation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10909851     DOI: 10.1038/sj.ejhg.5200496

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  10 in total

Review 1.  Disease-causing mutations in genes of the complement system.

Authors:  Søren E Degn; Jens C Jensenius; Steffen Thiel
Journal:  Am J Hum Genet       Date:  2011-06-10       Impact factor: 11.025

Review 2.  The X chromosome in immune functions: when a chromosome makes the difference.

Authors:  Claude Libert; Lien Dejager; Iris Pinheiro
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

3.  A novel mutation W388X underlying properdin deficiency in a Finnish family.

Authors:  M Helminen; S Seitsonen; H Jarva; S Meri; I E Järvelä
Journal:  Scand J Immunol       Date:  2012-04       Impact factor: 3.487

Review 4.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

5.  Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.

Authors:  Yuko Kimura; Takashi Miwa; Lin Zhou; Wen-Chao Song
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

6.  Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies.

Authors:  Carine El Sissy; Jérémie Rosain; Paula Vieira-Martins; Pauline Bordereau; Aurélia Gruber; Magali Devriese; Loïc de Pontual; Muhamed-Kheir Taha; Claire Fieschi; Capucine Picard; Véronique Frémeaux-Bacchi
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

Review 7.  The alternative complement pathway revisited.

Authors:  Morten Harboe; Tom Eirik Mollnes
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

Review 8.  Human genetics of meningococcal infections.

Authors:  Stephanie Hodeib; Jethro A Herberg; Michael Levin; Vanessa Sancho-Shimizu
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

9.  The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?

Authors:  Marloes A H M Michels; Elena B Volokhina; Nicole C A J van de Kar; Lambertus P W J van den Heuvel
Journal:  Pediatr Nephrol       Date:  2018-08-23       Impact factor: 3.714

10.  Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.

Authors:  Dennis V Pedersen; Trine A F Gadeberg; Caroline Thomas; Yong Wang; Nicolas Joram; Rasmus K Jensen; Sofia M M Mazarakis; Margot Revel; Carine El Sissy; Steen V Petersen; Kresten Lindorff-Larsen; Steffen Thiel; Nick S Laursen; Véronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.